Ask any quality director who’s launched a product in the EU for the first time about what surprised them most, and a good number will mention the same thing: how much legal weight sits behind a single signature.
In the U.S., batch disposition functions as a quality unit, while in the EU, it requires certification by a qualified person who assumes legal accountability for each batch released for sale. For pharmaceutical companies looking to enter or expand in the EU market, grasping the workings of QP services is crucial, particularly in deciding whether to seek local QP support or manage the function internally, as this decision can significantly impact launch schedules.
Roles and responsibilities of QP
The role of the Qualified Person (QP) is often simplified as “batch release,” but it encompasses a comprehensive certification process. The QP certifies that all evidence for a batch supports its release, ensuring compliance with EU GMP and the approved Marketing Authorisation or IMPD for investigational products. The QP verifies that any critical deviations have been investigated and resolved, that starting materials meet release requirements, and that traceability and data integrity are maintained throughout the production process.
In relation to releasing a batch, it is essential to review various documents, including batch records, deviation reports, and validation statuses, to ensure compliance with EU GMP standards before certification by a QP. This process is not merely a clerical task; it requires professional judgment that carries legal responsibility. Consequently, QPs must possess specific qualifications, including a relevant university degree and at least two years of practical GMP experience. In certain member states, only pharmacists can serve as QPs, in compliance with EU regulations. Every manufacturing authorization holder must have a QP available at all times.
Why “Local” QP Support Matters
EU pharmaceutical law is harmonized at the directive level but is separately transposed into national law by each of the 27 member states. This leads to variations in interpretation by national authorities regarding documentation, registration procedures, and local inspections of QP certification decisions.
Companies treating QP qualification as a uniform EU credential may face challenges, as batch release processes that work in one member state may not in another due to local regulatory nuances, despite a consistent GMP standard. A QP’s knowledge of specific market regulations is crucial for certification.
This is the practical case for local QP services. The advantages of having a QP who is experienced in the relevant member state for local QP services. Such a QP is more effective in managing registration processes, addressing inquiries from local authorities, and ensuring reliable certification timelines.
QP assists in the outsourcing department
A QP must be formally designated on a Manufacturer’s or Importer’s Authorisation (MIA) to certify batches. Companies often face a decision between building an in-house QP or outsourcing this role. Employing a QP requires significant commitment in terms of recruitment, training, and retention, especially for companies with smaller EU operations, early clinical supplies, or a single product line.
The alternative to establishing an in-house QP is to contract QP services from a provider with existing QPs on their MIA. In this model, the client’s product is incorporated into the provider’s authorization, and their QP team certifies batches after training on the client’s product and processes. This option is often preferable for companies, especially those conducting clinical trials or early commercial launches in the EU, as it avoids the time and costs associated with developing a dedicated QP function.
Providers may offer a hybrid path where a company’s qualified QP can be designated on the provider’s MIA, allowing the provider to oversee quality without certifying. The choice of model depends on the company’s EU volume, the number of markets being certified, and existing internal quality infrastructure.
What to look for in a QP service provider
Outsourced QP arrangements vary significantly, often revealing differences during inspections instead of routine releases. It’s important to assess various factors before selecting a provider.
- Confirm that QPs are specifically named on an active and relevant MIA, rather than just being labeled as “qualified” in a general context.
- Product-specific experience is crucial, as batch certification for small-molecule oral solids presents a different risk profile compared to biologics or advanced therapy medicinal products (ATMP), such as cell and gene therapies. It is essential to ensure that the provider’s QP team has direct experience with the relevant product class.
- Training rigor is essential; a responsible provider mandates a structured onboarding period for your specific product, process, and quality system prior to certification, rather than beginning the same week.
- Training rigor is essential; a responsible provider mandates a structured onboarding period for your specific product, process, and quality system before certification, rather than beginning the same week.
- Transparent quality oversight is essential. Regardless of whether the provider’s or your own QP is listed on the authorization, a well-documented quality oversight arrangement is necessary to ensure the defensibility of the relationship during inspection.
QP certification in the pharmaceutical industry serves as a critical endorsement, confirming that a batch’s entire production system functioned as intended. For companies in the EU, the focus rests not on the necessity of this certification, but on the qualifications of the certifying individual, their familiarity with the national regulatory landscape, and the robustness of their justification when questioned by authorities. Early, informed decisions regarding these factors can lead to significant time savings.
Zenovel offers local QP services in the EU to pharmaceutical companies for batch certification across EU member states. By utilizing their experienced QP network, clients can avoid the delays associated with establishing an in-house function. This network is adept in the EU GMP framework and the specific requirements of different markets, ensuring predictable batch release timelines and readiness for inspections. For tailored QP support, interested parties are encouraged to contact our team.
